These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26245497)

  • 1. Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies.
    Celio L; Bonizzoni E; De Braud F; Agustoni F; Aapro M
    Support Care Cancer; 2016 Mar; 24(3):1025-34. PubMed ID: 26245497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.
    Celio L; Frustaci S; Denaro A; Buonadonna A; Ardizzoia A; Piazza E; Fabi A; Capobianco AM; Isa L; Cavanna L; Bertolini A; Bichisao E; Bajetta E;
    Support Care Cancer; 2011 Aug; 19(8):1217-25. PubMed ID: 20574663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial.
    van der Vorst MJDL; Toffoli EC; Beusink M; van Linde ME; van Voorthuizen T; Brouwer S; van Zweeden AA; Vrijaldenhoven S; Berends JC; Berkhof J; Verheul HMW
    Oncologist; 2021 Jan; 26(1):e173-e181. PubMed ID: 32735029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial.
    Celio L; Denaro A; Agustoni F; Bajetta E
    J Support Oncol; 2012; 10(2):65-71. PubMed ID: 22005217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.
    Okada Y; Oba K; Furukawa N; Kosaka Y; Okita K; Yuki S; Komatsu Y; Celio L; Aapro M
    Oncologist; 2019 Dec; 24(12):1593-1600. PubMed ID: 31217343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials.
    Celio L; Bonizzoni E; Bajetta E; Sebastiani S; Perrone T; Aapro MS
    Support Care Cancer; 2013 Feb; 21(2):565-73. PubMed ID: 22869054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence.
    Celio L; Bonizzoni E; Zattarin E; Codega P; de Braud F; Aapro M
    BMC Cancer; 2019 Dec; 19(1):1268. PubMed ID: 31888544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
    Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
    Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
    Navari RM; Einhorn LH; Loehrer PJ; Passik SD; Vinson J; McClean J; Chowhan N; Hanna NH; Johnson CS
    Support Care Cancer; 2007 Nov; 15(11):1285. PubMed ID: 17375339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
    Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
    Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study.
    Kitayama H; Tsuji Y; Sugiyama J; Doi A; Kondo T; Hirayama M
    Int J Clin Oncol; 2015 Dec; 20(6):1051-6. PubMed ID: 25822106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
    Italian Group for Antiemetic Research
    N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
    Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
    BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials.
    van der Vorst MJ; Neefjes EC; Konings IR; Verheul HM
    Support Care Cancer; 2015 Aug; 23(8):2499-506. PubMed ID: 26041480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
    Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
    Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.